Announcement PDF RNS Number : 9877R N4 Pharma PLC 11 June 2024 N4 Pharma plc ("N4 Pharma" or the "Company") New Corporate Presentation N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that a new Corporate Presentation has been published. The Corporate Presentation can be viewed on the Company's interactive investor https://investors.n4pharma.com/activity-updates/n4-pharma-company-presentation-june-24 hub, at: For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director investors.n4pharma.com SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44(0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope Tel: +44(0)20 3657 0050 InvestorHub Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say. https://investors.n4pharma.com/link/YeNdZP About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market. For further information on the Company https://investors.n4pharma.com/auth/signup. visit www.n4pharma.com or sign up at This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRAEAEKFFFSLEFA